

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 38160

**Title:** History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan

**Reviewer's code:** 01555255

**Reviewer's country:** Italy

**Science editor:** Xue-Jiao Wang

**Date sent for review:** 2018-02-05

**Date reviewed:** 2018-02-07

**Review time:** 1 Day

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

- Title: to help the reader, i suggest to report "genotype 2" and not "GT2" - Introduction section: i suggest to briefly describe the epidemiology of genotypes in Japan, and the scheduled treatment with TVR and SOF. Recently was described that RVR was the only independent predictive factor of SVR, indipendly to liver fibrosis in HCV patients treated by triple therapy (Morisco et al. Rev Recent Clin Trials. 2016) - Patients section: the patients enrolld in the study, were treated now for the first time, or are present patients at the second treament? - Discussion section: the data here reported on SVR and its relationship with IL-28b, are in line with data previously published, in particular related with ethnicity?

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 38160

**Title:** History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan

**Reviewer's code:** 00068235

**Reviewer's country:** Pakistan

**Science editor:** Xue-Jiao Wang

**Date sent for review:** 2018-02-05

**Date reviewed:** 2018-02-08

**Review time:** 3 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

The manuscript entitled "History of HCC or INF based therapy attenuates SOF/RBV for GT2 HCV in Japan" by Yada et al is well written and well presented. Please incorporate following minor suggestions in your paper. Introduction 170 million HCV patients.. Figures are old. Add recent reference of WHO HCV figures which is around 130-150 million cases. In introduction add few lines about the WHO Global Health Sector strategy for the control of viral hepatitis, with 2020 and 2030 HCV treatment targets. Table 1: Characteristics of the patients. Can be replaced with Baseline or pretreatment characteristics of the patients. Please add a flow sheet diagram of your study. The paper is accepted for publication in WJG after minor revision. Yasir Waheed, PhD

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 38160

**Title:** History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan

**Reviewer's code:** 00071703

**Reviewer's country:** Turkey

**Science editor:** Xue-Jiao Wang

**Date sent for review:** 2018-02-05

**Date reviewed:** 2018-02-10

**Review time:** 5 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan In this study, the authors aimed to investigate the real-world efficacy and safety of sofosbuvir/ribavirin (SOF/RBV) therapy for Japanese patients with genotype 2 HCV (GT2-HCV). A total of 182 patients with GT2-HCV infection who received SOF/RBV therapy for 12 weeks had been enrolled in the study. Relationships between virological response and clinical data have been examined by logistic regression analyses. The authors have concluded that history of HCC or IFN-based therapy independently reduces the efficacy of this treatment. This manuscript is well written; also the figures and the tables are all appropriate.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 38160

**Title:** History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan

**Reviewer's code:** 03024603

**Reviewer's country:** Egypt

**Science editor:** Xue-Jiao Wang

**Date sent for review:** 2018-02-05

**Date reviewed:** 2018-02-14

**Review time:** 9 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

I revised the manuscript entitled "History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan" The study is important and interesting and well written I recommend its publication as it is

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 38160

**Title:** History of HCC or IFN-based therapy attenuates SOF/RBV for GT2-HCV in Japan

**Reviewer's code:** 02441021

**Reviewer's country:** Egypt

**Science editor:** Xue-Jiao Wang

**Date sent for review:** 2018-02-05

**Date reviewed:** 2018-02-21

**Review time:** 16 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Statistical analysis • Statistical analyses were performed using JMP software version 8.0.2 (SAS Institute Inc., Cary, NC, USA). .....elaborate on the abbreviations